Tagadtal, Husain M.
HRN: 21-51-02 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/24/2022
CEFUROXIME 1.5GM (VIAL)
06/24/2022
06/30/2022
IVTT
1.5
Q8
TB Spondylodiscitis
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointMultiple Infections (tick All Sites) Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes